Anti-interleukin-5 antibody therapy in eosinophilic diseases. - Wikidata - wikimedia - TriplyDB

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

http://www.wikidata.org/entity/Q36438486

about

Basic pathogenesis of eosinophilic esophagitis Lack of IL-4 receptor expression on T helper cells reduces T helper 2 cell polyfunctionality and confers resistance in allergic bronchopulmonary mycosis Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review.Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches.RNA interference against interleukin-5 attenuates airway inflammation and hyperresponsiveness in an asthma model.Oral mucosa lesions in hypereosinophilic syndrome--an update.Recent advances in the treatment of eosinophilic esophagitis [Eosinophilic esophagitis in 29 pediatric patients].Prolonged eosinophil production after allergen exposure in IFN-gammaR KO mice is IL-5 dependent.Rapid and strong induction of apoptosis in human eosinophils by anti-CD30 mAb-coated microspheres and phagocytosis by macrophages.

P2860

Q24672226-A58F0A88-9EB9-4CBD-AC1C-63C59EE74A53 Q28259791-690E43ED-9CB3-4F09-965C-5817EA7A5534 Q33780705-1664E34B-7E1D-450F-A3BB-45486686D919 Q36872864-4209CBD3-8E05-4672-9684-2BAFD77EE902 Q36899098-DF3FBE60-08FB-433D-9392-C810BFBFAB98 Q37037272-58EFA07C-8E4F-4E85-9B74-6FFE8F881D7C Q37056671-0E89E39B-0A7D-4907-BDF4-0D866C714E11 Q37275412-1D6A6981-9B65-4FF4-A1D4-7C55B80AC0AF Q46486747-1AD4103D-1006-4C2E-8EB5-E23B65212992 Q46650122-1AA8245A-EFD8-47BD-A678-572AB0A27910 Q50941359-0884756A-5B55-4524-BA71-9E78636203D8

P2860

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

http://www.wikidata.org/entity/Q36438486

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@ast

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@en

type

label

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@ast

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@en

prefLabel

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@ast

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@en

P1433

Q36438486-66047A14-DF27-4186-8411-EBE791BD46E7

P1476

Q36438486-8CB60C09-A681-43EC-9DC6-936E86068489

P2093

Q36438486-50CF4000-0D17-41B4-A01C-EECD110848F5

Q36438486-C0E1919A-67C0-4959-9DAD-4999B92DC942

P2860

Q36438486-0348379E-4781-4B3F-975B-1067306EA00D

Q36438486-0E0A5EC4-CA71-4587-8866-39547974629D

Q36438486-15AC476C-B76C-4E2A-BB96-8E36A0B2DE02

Q36438486-16041B89-EC56-42E7-A68F-EE850FFADC12

Q36438486-182BEA02-1598-42DC-9D4F-A78DBE3494A1

Q36438486-18DF110C-6597-4285-9936-4AAC5B199B68

Q36438486-1A8955B8-5606-47BC-913B-1F4A05DC88E7

Q36438486-1E64F351-56C6-4062-8188-2BA77390AAFC

Q36438486-1F349671-C13A-4A27-8C50-42584D11BFA4

Q36438486-29CDA863-EB96-4514-80B5-B4DC9B6F3A7C

P304

Q36438486-7B3183E4-0F95-4B52-BB47-477943497D59

P31

Q36438486-E24F6C20-5748-4FAC-BDE1-D6486D8230D1

P356

Q36438486-D319BFB2-8E13-4774-8FAB-0EDE3E253056

P433

Q36438486-961F1634-FFB3-460E-AB00-DCEA8F6B0A38

P478

Q36438486-42C5605B-00B3-4725-836E-0F74D7461899

P50

Q36438486-9474C24E-2517-4DFD-B388-59C9315254FB

P577

Q36438486-BDF62235-6F37-4934-A840-BD1CBD588BC7

P698

Q36438486-2898F89F-83FA-4722-B339-EAF443DF1527

P921

Q36438486-ee90c7ec-ec34-411b-a804-db0e3b3d0647

P356

P1433

P1476

Anti-interleukin-5 antibody therapy in eosinophilic diseases.

@en

P2093

Dagmar Simon

http://www.w3.org/2001/XMLSchema#string

Lasse R Braathen

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness

Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge

Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor alpha chain-deficient mice

Mechanisms of eosinophil-associated inflammation.

IL-5-induced airway eosinophilia--the key to asthma?

The trials and tribulations of IL-5, eosinophils, and allergic asthma.

A role for eosinophils in airway remodelling in asthma.

The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract.

Verdict in the case of therapies versus eosinophils: the jury is still out.

P304

287-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000091326

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16582580

http://www.w3.org/2001/XMLSchema#string

P921